Condition: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · Sponsor: Hoffmann-La Roche
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed by the treating physician to continue their BTKi throughout the screening period and for the first three cycles of mosunetuzumab. An additional arm (open to non-US participants only) has been added to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with venetoclax, a B-cell lymphoma 2 (BCL2) inhibitor.
This description comes directly from the study's public registry record.
Reference Study ID Number: BO43243 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | Withdrawn |
| The James Cancer Hospital and Solove Research Institute | Columbus, Ohio, United States | Recruiting |
| Uni of Texas - Md Anderson Cancer Center | Houston, Texas, United States | Withdrawn |
| Huntsman Cancer Institute at The University of Utah | Salt Lake City, Utah, United States | Recruiting |
| Princess Alexandra Hospital Woolloongabba | Woolloongabba, Queensland, Australia | Recruiting |
| Peter MacCallum Cancer Center | East Melbourne, Victoria, Australia | Completed |
| Monash Medical Centre | Melbourne, Victoria, Australia | Recruiting |
| Peking University People's Hospital | Beijing, China | Recruiting |
| Southern Medical University Nanfang Hospital | Guangzhou, China | Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, China | Recruiting |
| Tianjin Institute of Hematology & Blood Diseases Hospital | Tianjin, China | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05091424